Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma
2019 · Molecular Therapy — Oncolytics · 163 citations
https://doi.org/10.1016/j.omto.2019.08.002
Z
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
113
Papers
1.9K
Citations
19
h-index
31
i10-index
Zhitao Ying is an academic researcher from Chinese Academy of Medical Sciences & Peking Union Medical College. The author has contributed to research in topics: Lymphoma Diagnosis and Treatment & CAR-T cell therapy research & Viral-associated cancers and disorders. The author has an h-index of 19, co-authored 97 publications.
ORCID: 0000-0002-9794-7190Papers by this author
worksITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma
2019 · Cancer Cell International · 37 citations
https://doi.org/10.1186/s12935-019-0754-9
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma
2019 · Journal of Experimental & Clinical Cancer Research · 34 citations
https://doi.org/10.1186/s13046-019-1076-4
4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass
2015 · Blood · 11 citations
https://doi.org/10.1182/blood.v126.23.264.264
Clinical Response in Relapsed/Refractory (R/R) B-NHL Treated with the CD19-Directed CAR T-Cell Product JWCAR029
2019 · Blood · 8 citations
https://doi.org/10.1182/blood-2019-127751
Primary Clinical Response of Relmacabtagene Autoleucel in Adults with Relapsed/Refractory Follicular Lymphoma (r/r FL) in China
2021 · Blood · 2 citations
https://doi.org/10.1182/blood-2021-150085
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat